NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization78.57 mln
Float4.13 mln
Earnings Date10/29/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-0.43
Highly suspicious
Relative Strength
92
/ 100
Top performer
Debt / Equity
-0.27
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 2012 and based in Thousand Oaks, California, Atara Biotherapeutics is a clinical-stage company working to create new treatment options for patients with cancer and immune system disorders. Its most advanced program, tabelecleucel, uses the body's own immune cells to fight diseases caused by the Epstein-Barr virus, including a serious condition that can develop after organ or stem cell transplants. The company is also advancing a next-generation cell therapy aimed at certain blood cancers and autoimmune conditions, and conducts its research in partnership with two leading medical institutions.
